Project|21 - Mike Kope - Rejuvenation Biotechnology 2016

SENS Research Foundation CEO Mike Kope briefly introduces our major new initiative, Project|21, created to move the first SENS therapies into human clinical trials by 2021. Mike discusses the three components of Project|21 – Bridge|21, the Center of Excellence, and the Alliance Program – and the roles they will play in achieving that goal.